Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors

Immunotherapy. 2017 Mar;9(5):423-433. doi: 10.2217/imt-2017-0002.

Abstract

Radiotherapy is an established local treatment in patients with various malignancies. Systemic responses following local irradiation have been described as abscopal effects. Modern cancer immunotherapy with immune checkpoint inhibitors has shown impressive response rates and prolongation of survival even in heavily pretreated patients with advanced solid malignancies and lymphomas. Radiotherapy has been shown to modulate immune response, and its application in the context of immune checkpoint inhibition has recently evolved into an active field of research. Prospective studies investigating combination treatment are currently ongoing and will answer questions as to the optimal schedule and radiation dosing. This short review focuses on the immunomodulatory role of radiotherapy and the use of immune checkpoint inhibition with a special focus on Hodgkin lymphoma.

Keywords: Hodgkin lymphoma; abscopal effect; radio-immunotherapy.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Cell Cycle Checkpoints / drug effects*
  • Combined Modality Therapy
  • Drug Synergism
  • Growth Inhibitors / therapeutic use*
  • Hodgkin Disease / immunology
  • Hodgkin Disease / therapy*
  • Humans
  • Radioimmunotherapy*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Growth Inhibitors